Valofane
From Wikipedia, the free encyclopedia
|
Valofane
|
|
| Systematic (IUPAC) name | |
| N-carbamoyl-5-methyl-2-oxo-3-prop-2-enyloxolane-3-carboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C10H14N2O4 |
| Mol. mass | 226.229 g/mol |
| Synonyms | Valofan, Valofane |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Valofane is a sedative drug structurally related to the barbiturates[1] and similar drugs such as primidone. It is metabolised once inside the body to form the barbiturate proxibarbal and is thus a prodrug.[2]
[edit] References
- ^ Traversa U, Puppini P, Jacquot C, Vertua R. Effect of an atypical barbiturate, the 2-allophanyl-2-allyl-4-valerolactone (valofan), on exploratory behaviour and brain serotonin concentrations in mice. Journal de Pharmacologie. 1985 Jul-Sep;16(3):279-90.
- ^ Lambrey B, Compagnon PL, Jacquot C. Pharmacokinetics of 14C-2-allophanyl-2-allyl -gamma-valero-lactone: a prodrug of proxibarbal in rats. European Journal of Drug Metabolism and Pharmacokinetics. 1981;6(3):161-9.
|
|||||

